Liming Wang

10PUBLICATIONS
19CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyCancer cell biologyMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 05, 2026
Dihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases.

|Apr 11, 2026
Efficacy and Safety of Intensity-Modulated Radiotherapy Combined With Regorafenib With or Without Immune Checkpoint Inhibitors as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Real-World Cohort Study From a Single Center.

Lingxia Xin, Zhiyu Li, Yirui Zhai

|Mar 30, 2026
Cancer-Associated Fibroblasts in the Treatment of Intrahepatic Cholangiocarcinoma: Present and Prospects.

Yimeng Yuan, Ruoyu Zhang, Chengkang Qu

|Jan 09, 2026
VIRMA/IGF2BP3-mediated ANLN upregulation promotes intrahepatic cholangiocarcinoma growth by forming a positive feedback loop with RhoA/YAP1/TEAD1 signaling pathway.

Jiajun Zhang, Ning Huang, Lin-Rui Gao

|Jul 09, 2024
Tumor purity-related genes for predicting the prognosis and drug sensitivity of DLBCL patients.

Zhenbang Ye, Ning Huang, Yongliang Fu

|Feb 23, 2024
HBV integrations reshaping genomic structures promote hepatocellular carcinoma.

Zhaoyang Qian, Junbo Liang, Rong Huang

Pageof 2

Frequent Collaborators

3 joint publications

Mei Liu

2 joint publications

Jianxiong Wu

2 joint publications

Ning Huang

1 joint publications

Ye-Xiong Li